Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • FINALGON ® - Low Back Pain
    Clinical Study Number 69.52
    Study Indication Low Back Pain
    Product FINALGON ®
    Generic Name Nicoboxil + Nonivamide
    Lab Code
    Clinical Phase IIIb
    Study Title

    A multi-centre, double-blind, randomised, parallel group study to assess the efficacy and safety of multiple doses of topically applied hyperemisation-inducing ointment (2cm ointment line per application; up to 3 times daily for up to 4 days) containing 2.5% Nicoboxil/0.4% Nonivamide versus 2.5% Nicoboxil, 0.4% Nonivamide and placebo in patients 18 to 65 years of age with acute low back pain

    Study Document
    Trial synopsis 69.52_DR english
  • FINALGON ® - Low Back Pain
    Clinical Study Number 69.53
    Study Indication Low Back Pain
    Product FINALGON ®
    Generic Name Nicoboxil + Nonivamide
    Lab Code
    Clinical Phase III
    Study Title

    A multinational, randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of multiple doses of Finalgon® cream (1.08% Nicoboxil / 0.17% Nonivamide) in the treatment of acute low back pain

    Study Document
    Trial synopsis 69.53 english